Please note: We are currently experiencing some performance issues across the site, and some pages may be slow to load. We are working on restoring normal service soon. Importing new articles from Word documents is also currently unavailable. We apologize for any inconvenience.

loading page

Emergent data influences the risk/benefit assessment of hemophilia gene therapy using recombinant adeno-associated virus.
  • John Puetz
John Puetz

Corresponding Author:[email protected]

Author Profile